ChatGPTなどを活用して業務のAI化を進めています。プロンプトエンジニアリングの専門家です！と、名乗れるレベルではありませんが、かなり色々使いこなしてきています。病気で失われた能力は、別な能力を発達させる、進化することで生き残っていこうと思います。
<><><>
<>
24/11/16
[HTML] The role of epithelial-mesenchymal transition in pulmonary fibrosis: lessons from idiopathic pulmonary fibrosis and COVID-19
R Niayesh-Mehr, M Kalantar, G Bontempi, C Montaldo… - Cell Communication and …, 2024
… Their activity has been implicated in the pathogenesis of PF in a variety of lung disorders, including idiopathic pulmonary fibrosis (IPF) and … PF is a characteristic aspect of idiopathicpulmonary fibrosis (IPF). IPF is the most common and severe …
- 肺線維症における上皮間葉転換の役割：特発性肺線維症とCOVID-19からの教訓
Modulating Fibrotic Mechanical Microenvironment for Idiopathic Pulmonary Fibrosis Therapy
XN Li, YP Lin, MM Han, YF Fang, L Xing, JH Jeong… - Advanced Materials, 2024
… Idiopathic pulmonary fibrosis (IPF) is exacerbated by injurious mechanical forces that destabilize the pulmonary mechanical microenvironment … a promising strategy for modulating pulmonary mechanical microenvironment but also pioneers …
- 特発性肺線維症治療のための線維性機械的微小環境の調節
Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry
C Sack, DM Wojdyla, MG MacMurdo, A Gassett… - Annals of the American …, 2024
… is a known risk factor for adverse pulmonary outcomes, its impact in individuals with idiopathic pulmonary fibrosis (IPF) is less well … IPF-PRO Registry, a prospective observational registry that enrolled individuals with IPF at 46 US sites …
- 長期大気汚染曝露と特発性肺線維症の重症度: IPF-PRO レジストリのデータ
[HTML] … Histone Deacetylase Inhibitors as New Antifibrotic Agents: Biological Evaluation in Human Fibroblasts from Bronchoalveolar Lavages of Idiopathic Pulmonary Fibrosis …
A Fontana, L Bergantini, G Carullo, L Scalvini… - ACS Pharmacology & …, 2024
… Idiopathic pulmonary fibrosis (IPF) is a rare interstitial lung disease typified by a progressive fibrosing phenotype. IPF has been associated with … of fibrotic markers, fibronectin and collagen 1, in fibroblasts derived from bronchoalveolar lavages of …
- スピロテトラヒドロイソキノリン系ヒストン脱アセチル化酵素阻害剤による新規抗線維化剤：特発性肺線維症患者の気管支肺胞洗浄液から採取したヒト線維芽細胞における生物学的評価
[HTML] Antifibrotic drug treatment of patients with idiopathic pulmonary fibrosis in Sweden: A registry-based observational study
L Carlson, D Kalafatis, I Pesonen, JM Magnusson… - Chronic Respiratory …, 2024
… Idiopathic pulmonary fibrosis (IPF) is characterized by progressive fibrosis of the lung … characteristics and antifibrotic treatment strategies during the first years after IPFdiagnosis. … Idiopathic pulmonary fibrosis(IPF) is characterized by progressive …
- スウェーデンにおける特発性肺線維症患者に対する抗線維化薬治療：登録ベースの観察研究
Lung resident mesenchymal stem cells in idiopathic pulmonary fibrosis
G Escarrer-Garau, A Martín-Medina, J Truyols-Vives… - 2024
… to idiopathic pulmonary fibrosis (IPF) by differentiating into myofibroblasts. Our transcriptomic analysis supported this since mesenchyme development and collagen metabolism were two different biological processes between IPF and …
- 特発性肺線維症における肺常在間葉系幹細胞
Radiological and histopathological features of Early Idiopathic Pulmunary Fibrosis (Early IPF)
MM Marinato, B Stefani, L Tofani, A Sorano, L Gori… - 2024
… of 326 consecutive patients diagnosed with IPF at AOU Careggi, … IPF have a significantly higher percentage of indeterminate UIP patterns (31,43%). From a histopathological point of view, early IPF have significantly lower prevalence of …
- 早期特発性肺線維症（早期IPF）の放射線学的および組織病理学的特徴
The effectiveness of respiratory training in idiopathic pulmonary fibrosis: a exercise capacity meta-analysis
JM Núñez, JR Benítez, GV Peña, AH Ciurí, AN Otero… - 2024
… Results: We included 4 studies, which included 255 patients with idiopathicpulmonary fibrosis. The pooled mean difference showed … -analysis showed a beneficial effect of respiratory training for improving exercise capacity of the …
- 特発性肺線維症における呼吸トレーニングの有効性：運動能力メタ分析
… the variance in protein expression profiles between patients diagnosed with idiopathic pulmonary fibrosis (IPF) and those with non-IPF interstitial lung diseases (ILD)
TH Yen, PK Fu - 2024
… Among these, idiopathic pulmonary fibrosis(IPF) represents a primary category of F-ILD, and together with non-IPF ILD, they share similar … Our objective is to investigate the variances in protein expression profiles between IPF and non-IPF …
- 特発性肺線維症（IPF）と診断された患者と非IPF間質性肺疾患（ILD）の患者間のタンパク質発現プロファイルの差異を分析す
End-of-life of patients with idiopathic pulmonary fibrosis treated with antifibrotic therapy
M Sato, Y Koga, Y Hachisu, K Takehara, I Wakamatsu… - 2024
… Background: Idiopathic pulmonary fibrosis(IPF) is a progressive disease with high symptom burden and poor prognosis. Although antifibrotic drugs have … Objectives: We aimed to describe the end-of-life situation of IPF patients, focused on …
- 抗線維化療法を受けた特発性肺線維症患者の終末期
24/11/14
[HTML] Computed tomography morphological assessments of central airways in interstitial lung abnormalities and idiopathic pulmonary fibrosis
T Maetani, N Tanabe, K Tanizawa, R Sakamoto… - Respiratory Research, 2024
… outcomes in patients with idiopathicpulmonary fibrosis (IPF). This study aimed to compare central airway structure comprehensively between patients with IPF, subjects with … We further examined the prognostic impact of IPF-specific CT airway …
- 間質性肺疾患および特発性肺線維症における中心気道のコンピュータ断層撮影による形態学的評価
[HTML] Serum soluble isoform of receptor for advanced glycation end product is a predictive biomarker for acute exacerbation of idiopathic pulmonary fibrosis: a German and …
E Kitadai, K Yamaguchi, S Ohshimo, H Iwamoto… - Respiratory Research, 2024
… of idiopathic pulmonary fibrosis (IPF) and increased disease susceptibility to interstitial lung disease, respectively. However, whether sRAGE and RAGE SNP rs2070600 are associated with acute exacerbation of IPF (AE-IPF) … 234 patients …
- 終末糖化産物受容体の血清可溶性アイソフォームは特発性肺線維症の急性増悪の予測バイオマーカーである：ドイツと日本のコホート研究
A Tale of Two Mice: genetics of model mouse strains suggest a transcriptional basis for risk and resistance in idiopathic pulmonary fibrosis
T Fennell, I Beržanskytė, R Gam, W Zhu, M Sung… - 2024
… In this analysis, it is shown that the diagnostic markers of idiopathic pulmonary fibrosis (IPF) can be captured at the cellular level as enrichment for transcripts implicated in inflammation or tissue scarring (10, 60–62), among genes differentially …
- 2匹のマウスの物語: モデルマウス系統の遺伝学は特発性肺線維症のリスクと耐性の転写基盤を示唆している
Changes in lung function and mortality risk in patients with idiopathic pulmonary fibrosis (IPF)
JM Oldham, ML Neely, D Wojdyla, M Gulati, P Li… - 2024
… IPF is a progressive fibrosing interstitial lung disease associated with lung function decline and death. Aim: Examine the relationship between changes in lung function and mortality risk in a real-world cohort of patients with IPF… suggest that in …
- 特発性肺線維症（IPF）患者の肺機能の変化と死亡リスク
Idiopathic Pulmonary Fibrosis in the United Kingdom: Findings from the first decade of the largest single-country IPF Registry
A Fahim, M Loughenbury, S Agnew, H Almond… - 2024
Introduction: Idiopathic Pulmonary Fibrosis(IPF) is the most common progressive interstitial lung disease (ILD) and has a dismal prognosis. We reviewed data from the UK ILD Registry and present changes over time. Methods: Participating centres …
- 英国における特発性肺線維症：単一国としては最大のIPF登録の最初の10年間の調査結果
Prevalence and predictors of response to long-term treatment in patients with idiopathic pulmonary fibrosis (IPF).
E Cocconcelli, N Bernardinello, P Cameli, T Pianigiani… - 2024
… The natural history of IPF remains unpredictable despite antifibrotic treatment. In addition, some … To evaluate the functional trajectory of IPF patients treated with antifibrotics (nintedanib or … This multicenter study enrolled IPF patients provided …
- 特発性肺線維症（IPF）患者における長期治療に対する反応の有病率と予測因子。
Deep learning in the diagnosis of idiopathic pulmonary fibrosis
G Ozduygu, G Arı, N Bayhan, S In, H Tiryaki, AA Demir… - 2024
… Introduction: The diagnosis of idiopathicpulmonary fibrosis (IPF) mostly based on subjective data and … in pulmonary fibrosiswill contribute to early diagnosis and improve prognosis. Aims and objectives: We aim to standardize diagnosis of the UIP …
- 特発性肺線維症の診断におけるディープラーニング
Late Breaking Abstract-Antifibrotic Therapy and Risk of Lung Cancer in Patients with Idiopathic Pulmonary Fibrosis
S Kijlertsuphasri, T Petnak, T Moua - 2024
… idiopathic pulmonary fibrosis (IPF) than in the general population. Antifibrotics including pirfenidone and nintedanib have been approved for the treatment of IPF. Aims and Objectives: Our study aims to assess the impact of antifibrotics on lung …
- 最新速報抄録 - 特発性肺線維症患者における抗線維化療法と肺癌リスク
Mass spectrometry (MS)-based proteomics and mortality analysis in idiopathic pulmonary fibrosis (IPF)
B Gansen, AA Menon, H Mulder, ML Neely… - 2024
… may be associated with mortality in patients with IPF. Methods: The cohort included 299 patients from the IPF-PRO Registry. Proteins were … Conclusions: MS-based proteomic analyses confirmed known and identified new candidate biomarkers of …
- 特発性肺線維症（IPF）における質量分析（MS）ベースのプロテオミクスと死亡率分析
Late Breaking Abstract-Survival in Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Interstitial Lung Disease
RG Carbone, R Filiberti, S Chiola, GL Pariscenti… - 2024
… Median survival was 48.7 and 99.4 months in IPF-UIP (53 dead) and CTD-ILD (9 dead), respectively (p<0.001). Significant prognostic … Conclusions: Survival was significantly shorter in IPF-UIP than in CTD-ILD and negatively associated with …
- 最新速報抄録 - 特発性肺線維症および結合組織疾患 - 間質性肺疾患における生存
24/11/13
Role of hypusine signaling in idiopathic pulmonary fibrosis
SE Lemay, WH Wu, S Martineau, M Sauvaget… - 2024
… We hypothesized that hypusine signaling is increased in IPF and promotes parenchymal and vascular … of IPF patients and animal models (bleomycin (BLM)-treated mice, BLM+MCT-treated rats). We found that pharmacological inhibition of DHPS (GC7) …
- 特発性肺線維症におけるヒプシンシグナル伝達の役割
Decline in forced vital capacity (FVC) in subjects with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) compared with healthy references
C Valenzuela, F Bonella, CC Moor, G Weimann… - 2024
… Aim: Compare baseline FVC and decline in FVC in subjects with IPF in the INPULSIS trials and with PPF in the INBUILD trial with values … Conclusions: These data show the physiological impact of IPF and PPF and support the clinical …
- 特発性肺線維症（IPF）および進行性肺線維症（PPF）の患者における努力肺活量（FVC）の健常者との比較における低下
Sirtuins as biomarkers of accellerated cellular senescence in patients with Idiopathic Pulmonary Fibrosis (SIR-IPF)
DF Mariniello, V D'Agnano, F Scialò, G Mazzeo… - 2024
Background: Idiopathic Pulmonary Fibrosis(IPF) is a progressive lung disease characterized by deposition of fibrotic tissue in the lungs. Sirtuins a family of proteins involved in different enzymatic reactions might have a role as biomarker of …
- 特発性肺線維症（SIR-IPF）患者における細胞老化の加速のバイオマーカーとしてのサーチュイン
Do proteolytic enzymes affect the development of idiopathic pulmonary fibrosis.
O Karasova, V Rodionova, H Karasova, V Dmitrichenko… - 2024
Background: An important role in the development of idiopathic pulmonary fibrosisbelongs to the destruction of proteins of the extracellular matrix (ECM) by proteolytic enzymes. Purpose: to investigate the indicators of blood trypsin-like activity (TPA) …
- タンパク質分解酵素は特発性肺線維症の発症に影響しますか。
Impact of Indoor Air Pollution on Health Outcomes in Patients with Idiopathic Pulmonary Fibrosis
H Yoon, K Kim, SY Kim, SW Park, SM Choi, J Park… - 2024
… (PM 2.5), on patients with idiopathicpulmonary fibrosis (IPF) are unclear. Our study aimed to investigate the effects of indoor PM2.5 on the health outcomes in IPF patients. Methods: This multicenter prospective cohort study included 142 IPF …
- 特発性肺線維症患者の健康状態に対する室内空気汚染の影響
Nutritional assessment of patients with Idiopathic pulmonary fibrosis and nutritional supplements
JL Garcia, MS Romero, DEV Lizarazo, RF Jiménez… - 2024
Idiopathic pulmonary fibrosis (IPF) shows certain factors that may … IPF by measuring nutritional status and body composition using novel techniques (BIVA) for improved diagnosis and intervention. Materials and methods: Prospective baseline …
- 特発性肺線維症患者の栄養評価と栄養補助食品
Clinical Significance of 30-Second Sit-to-Stand Test in Patients with Idiopathic Pulmonary Fibrosis
ÖE Harputlu, B Akinci, GK Aslan, MS Arslan, G Okumuş - 2024
… -Sec-STS) on clinical parameters in patients with idiopathic pulmonary fibrosis (IPF). Method: Twenty-eight patients with IPF (eight women and twenty men, … In addition, we showed the predictor role of 30Sec-STS on dyspnea severity (mMRC) which is a …
- 特発性肺線維症患者における30秒間の座位・立位テストの臨床的意義
Radiology screening scale for usual interstitial pneumonia as an additional tool for establishing the diagnosis of pulmonary fibrosis in patients with post-COVID-19 ILD …
O Yakovenko, Y Dziublyk, E Khodosh, T Yakovenko… - 2024
… (ILD) and led to a diagnostic dilemma in the diagnosis of pulmonary fibrosis (PF). Despite the fact that PF has distinct radiological patterns (… as well as as an action algorithm for an artificial intelligence program to interpret radiological patterns of …
Design of the FIBRONEER-ON open-label extension trial of nerandomilast (BI 1015550)
WA Wuyts, L Richeldi, S Assassi, A Azuma, V Cottin… - 2024
… Background: There is a need for more effective treatments for idiopathic pulmonaryfibrosis (IPF) and progressive pulmonaryfibrosis (PPF). Nerandomilast (BI 1015550), an oral preferential inhibitor of PDE4B, is being evaluated in two …
- ネランドミラストの FIBRONEER-ON オープンラベル延長試験の設計 (BI 1015550)
Clinical evaluation of interstitial lung disease using 18F-FDG PET/CT
M Matsumoto, M Morikawa, S Yamazaki, S Ito… - 2024
… Results: We retrospectively analyzed 56 ILD cases in 44 patients (38 males, 6 females; mean age, 74.0 years), namely idiopathic pulmonaryfibrosis (32 cases), collagen-vascular disease-associated lung fibrosis (9), radiation pneumonitis (6) …
- 18F-FDG PET/CTを用いた間質性肺疾患の臨床評価
24/11/12
Impact of pulmonary hypertension in baseline characteristics and survival of patients with idiopathic pulmonary fibrosis
A Arvanitaki, G Diller, V Kouranos, T Semple, W Li… - 2024
… IPF and precapillary PH and 65 controls (IPFwithout PH, excluded with echocardiography and/or RHC) matched for age, sex and forced vital capacity were included (Figure 1A). Compared to their matched controls, patients with IPF-… More …
- 特発性肺線維症患者のベースライン特性と生存に対する肺高血圧の影響
Expression of HOXB7 in the lung of patients with idiopathic pulmonary fibrosis: a proof-of-concept study and clinical significance
G Bruzzi, R Tonelli, AV Samarelli, G Raineri, I Mastrolia… - 2024
… of IPF patients. Methods: Immunohistochemical (IHC) analysis was run on lung tissue samples from surgical lung biopsy (SLB) of 19 patients with IPF selected from the IPF … Results: IHC quantification showed that HOXB7 signal intensity was …
- 特発性肺線維症患者の肺における HOXB7 の発現: 概念実証研究と臨床的意義
Using FDG PET/CT for assessment of idiopathic pulmonary fibrosis disease activity and prediction of prognosis
JY Huang, CK Huang - 2024
… Background: Idiopathic pulmonary fibrosis(IPF) is a specific form of chronic, progressive fibrosing … Some studies suggested that FDG PET scans may be helpful in the evaluation of IPF and … indicator was defined in IPF, so we evaluated …
- FDG PET/CTを用いた特発性肺線維症の疾患活動性評価と予後予測
Nutritional assessment as a predictor of mortality in idiopathic pulmonary fibrosis
DEV Lizarazo, EC César, RF Jimenez, JL Garcia… - 2024
… Malnutrition are one of the most common comorbidities associated with idiopathicpulmonary fibrosis (IPF). Phase Angle (PhA), measured … The aim of this study is to determine the prognostic value of morphofunctional techniques in predicting …
- 特発性肺線維症における死亡率の予測因子としての栄養評価
[PDF] Targeting Autotaxin and LPA in Pulmonary Fibrosis: Admilparant's Positive Results Show Continued Promise
PL Molyneaux, P Spagnolo - American Journal of Respiratory and Critical Care …, 2024
… Current therapies for Idiopathic pulmonaryfibrosis (IPF) and Progressive PulmonaryFibrosis (PPF) have revolutionized the therapeutic … Despite an ever-growing number of trials of novel antifibrotic (and anti-inflammatory) therapies, drug …
- 肺線維症におけるオートタキシンとLPAの標的化：アドミルパラントの良好な結果は継続的な期待を示している
Prevalence and risk factors of progressive pulmonary fibrosis (PPF) in patients with Interstitial Lung Disease (ILD) in a tertiary care center in India
DJ Christopher, S Vijayasree, B Isaac, A Barney… - 2024
… Background: A subset of patients with ILDs other than Idiopathic Pulmonary Fibrosis (IPF) … We reviewed the clinical, lab & imaging data of all non-IPF patients and identified those who … Results: In all, there were 558 patients with ILD (IPF=56 …
- インドの三次医療センターにおける間質性肺疾患（ILD）患者における進行性肺線維症（PPF）の有病率とリスク因子
Quantitative Computed Tomography Analysis in Rheumatoid Arthritis-Related Interstitial Lung Disease
SM Humphries, A Adegunsoye, MK Demoruelle… - CHEST, 2024
… The DTA method was trained using manual annotations by 63 expert thoracic radiologists providing examples of reticulation, honeycombing and traction 64 bronchiectasis in CT scans of patients with idiopathic pulmonaryfibrosis (IPF). In …
- 関節リウマチ関連間質性肺疾患における定量的コンピュータ断層撮影分析
Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through systemic modulation of monocyte phenotypes
N Mansouri, G Willis, A Fernandez-Gonzalez, M Reis… - 2024
… Rationale: Mesenchymal stromal/stem cell (MSC) therapy has shown promise in experimental models of idiopathic pulmonaryfibrosis (IPF), a … Objectives: To test the therapeutic effects of MSC-exosomes (MEx) in a bleomycin-induced pulmonary …
- 間葉系間質細胞エクソソームは単球表現型の全身的調節を通じて実験的肺線維症を予防し、回復させる
Association of Pulmonary Hypertension risk on Echocardiography with the degree of pulmonary fibrosis in a Usual Interstitial Pneumonia Cohort in United Arab …
GS Bodi, M Samiuddin, H Alazazzi, S Mull, S Khan… - 2024
… Introduction: Pulmonary hypertension (PH) is common in patients with advanced IdiopathicPulmonary Fibrosis (IPF),ranging from 30 to 50 percent. There remains a significant knowledge gap in association of lung fibrosis specifically in Usual …
Pirfenidone and risk of lung cancer development in IPF: a nationwide population-based study
HY Yoon, H Kim, Y Bae, JW Song - European Respiratory Journal, 2024
… Idiopathic pulmonary fibrosis (IPF) carries a high risk of lung cancer, but the effect of pirfenidone on lung cancer development remains uncertain. We investigated the association between pirfenidone use and lung cancer development in patients with …
- ピルフェニドンとIPFにおける肺がん発症リスク：全国規模の人口ベースの研究
24/11/11
[PDF] Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF study
L Lancaster, V Cottin, M Ramaswamy, WA Wuyts… - Therapeutic Advances in …, 2024
What is this summary about? This plain language summary shares results from a clinical study called INTEGRIS-IPF that was published in the American Journal of Respiratory and Critical Care Medicine in 2024. This study looked at a medicine …
- 特発性肺線維症（IPF）患者におけるベキソテグラスト：INTEGRIS-IPF研究の発表の平易な要約
Molecular characterization of PANoptosis-related genes associated with immune infiltration and prognosis in idiopathic pulmonary fibrosis
H Chen, Z Xia, B Qing, L Gu, Y Chen, J Wang, Y Yuan - International …, 2024
… Idiopathic pulmonary fibrosis (IPF) is a chronic pulmonary disease with unknown … ) associated with immune infiltration and prognosis in IPF, while also establishing a novel prognostic … This study suggests that PANoptosis plays a role in IPF …
- 特発性肺線維症における免疫浸潤と予後に関連するPANoptosis関連遺伝子の分子特性
Convergent and divergent immune aberrations in COVID-19, post-COVID-19-Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis
B Tourki, M Jia, T Karampitsakos, IM Vera, A Arsenault… - American Journal of …, 2024
… cells associated with pulmonary fibrosisresolution post COVID-19 versus 89 progressive forms of pulmonary fibrosis such as IPF. In the … Valida on of a 52- 509 gene risk profile for outcome predic on in pa ents with idiopathicpulmonary fibrosis …
- COVID-19、COVID-19後の間質性肺疾患および特発性肺線維症における収束的および発散的な免疫異常
Safety and tolerability of bexotegrast in Phase 2 trials of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC)
G Cosgrove, R Pencek, C Barnes, A Clark, H Achneck… - 2024
Background: Bexotegrast (BEXO), an oral, once-daily, dual-selective inhibitor of integrins αvβ6 and αvβ1, has been studied in >700 participants from Phase 1 and Phase 2 trials in IPF and PSC Objectives: We report integrated safety and tolerability …
- 特発性肺線維症（IPF）および原発性硬化性胆管炎（PSC）の第2相試験におけるベキソテグラストの安全性と忍容性
Frequency of lung cancer in idiopathic pulmonary fibrosis
Z Bingol, G Altan, A Pihtili, E Kiyan, Z Kilicaslan… - 2024
Introduction: Lung cancer is 5-7 times more common in cases with IPF than the normal population. Aims: We aimed to investigate the frequency, subtypes, risk factors of lung cancer and effect on survival in IPF. Methods: Demographics, GAP …
- 特発性肺線維症における肺がんの頻度
Radiologic features associated to progressive fibrosing interstitial lung diseases (ILDs) other than Idiopathic Pulmonary Fibrosis (IPF)
S Bellani, E Cocconcelli, N Bernardinello, C Giraudo… - 2024
Background: A proportion of patients with ILD other than IPF may develop a progressive fibrosing phenotype, which is associated with a poor prognosis. Aim: To explore which radiologic features on initial chest CT scan are associated with …
- 特発性肺線維症（IPF）以外の進行性線維化性間質性肺疾患（ILD）に関連する放射線学的特徴
… acid receptor 1 (LPA1) antagonism on biomarkers in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF): data from a …
TM Maher, N Kaminski, F Wang, T Yarra, B Elpers… - 2024
… BMS-986278 groups vs PBO separately in the IPF and PPF cohorts. Results: In the IPF cohort, significant biomarker changes relative to PBO … with IPF, and biomarkers of inflammation and fibrosis in patients with PPF, consistent with effective …
- 特発性肺線維症（IPF）および進行性肺線維症（PPF）患者のバイオマーカーに対するリゾホスファチジン酸受容体1（LPA1）拮抗作用の影響：BMS-986278を用いたランダム化第2相試験のデータ
[HTML] 17 (18)-Epoxyeicosatetraenoic acid attenuates profibrotic signaling in idiopathic pulmonary fibrosis
문수진 - 2024
… However, the role of 17(18)-EpETE in idiopathic pulmonary fibrosis (IPF) remains … Results: The levels of 17(18)-EpETE in IPF lung tissue were significantly reduced compared to … -fibrotic effects on pulmonary fibrosis by suppressing fibroblast …
- 17（18）-エポキシエイコサテトラエン酸は特発性肺線維症における線維化促進シグナル伝達を減弱させる
Quantifying the effect of pirfenidone treatment on bleomycin-induced pulmonary fibrosis mice model in vivo using a novel synchrotron-based imaging method
X Luan, MA Webb, FN Herriot, V Marcoux, JS Tam… - 2024
… Synchrotron-based DEI-MIR provides a non-invasive quantitative assessment tool for testing the effect of current treatment for idiopathicpulmonary fibrosis (IPF) in small rodent models; and this imaging technique could be used for developing new …
Increased lung monocyte infiltration in Fibrotic Interstitial Lung Diseases.
E Vasarmidi, E Tsitoura, M Lourou, I Argyriou… - 2024
… role in idiopathic pulmonary fibrosis(IPF) pathogenesis is not yet understood. Current data suggest that high blood monocyte count in IPF … 201 patients with IPF and 144 with non-IPFfibrotic ILDs (chronic hypersensitivity pneumonitis, ILD …
- 線維性間質性肺疾患における肺単球浸潤の増加。
<>
<><><>
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。GoogleのAIが一定の重み付けはしているとは思いますが、玉石混交です。
当面、毎週アラートの内容をアップしていこうと思います。
###
